Clinical Trials of Safety and Efficacy of Oral WR 6026 in Treatment of Visceral Leishmaniasis.
Abstract
Under this Cooperative Agreement, the efficacy of an oral 8-aminoquinoline (8.((6-(diethylamino)hexyl)amino)-6-methoxy-4-methylquinoline)(WR6O26) in the treatment of 16 patients with kala azar was evaluated. The first 8 patients received therapy for 2 weeks at a dosage of 0.75-1.00 mg/(kg.day); 1 patient was cured, and in the other 7, a 1-logarithm decrease in the number of splenic parasites and clinical improvement were noted. The next 8 patients received therapy for 4 weeks at the same daily dosage (1 mgl(kg.day)); 4 were cured, and of the other 4 patients, 1- to 2-log decreases in the number of parasites and clinical improvement were noted. The therapy was associated with minimal toxicity; adverse effects included gastrointestinal distress, headache, and methemoglobinemia. The fact that one-half of the patients were cured indicates that future trials with longer regimens and higher dosages are warranted and should include patients for whom existing treatment methods have failed.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 31, 1992
- Accession Number
- ADA309891
Entities
People
- J. B. Were
Organizations
- Kenya Medical Research Institute